Introduction
A family of cysteine proteases, known as caspases, plays an important role in many forms of cell death by apoptosis and proinflammatory cytokine maturation (Thornberry and Lazebnik, 1998) . So far, 14 caspases have been identified in mammalian cells, of which 12 human enzymes are known (Nicholson, 1999) . The second identified mammalian caspase, known as caspase-2 , was initially referred to as Nedd-2 in mice (Kumar et al., 1992) and Ich-1 (interleukin-lb converting enzyme homolog 1) in humans (Wang et al., 1994) . Nedd-2 was originally identified as a developmentally regulated gene in mouse brain (Kumar et al., 1992) . The human CASP-2 gene, Ich-1, encodes at least two different forms of mRNA species derived from alternative splicing in the 3 0 region (Wang et al., 1994) . Overexpression of the long isoform caspase-2L was shown to induce programmed cell death (Kumar et al., 1994) , whereas its decreased expression by antisense technology delayed apoptosis in response to various stimuli (Kumar, 1995; Troy et al., 2000; Droin et al., 2001a) . Conversely, overexpression of the short isoform, caspase-2S, could suppress mammalian cell death (Wang et al., 1994; Kumar, 1995; Droin et al., 2001b) . Experiments using caspase-2-knockout mice showed that oocytes were resistant to cell death induced by cytotoxic drugs and that B lymphoblasts were resistant to perforin-and granzyme B-induced apoptosis whereas cell death was accelerated in some neuronal populations (Bergeron et al., 1998; Morita et al., 2001) . Altogether, these observations indicate that caspase-2 may act both as a positive and a negative regulator of programmed cell death, depending on cell lineage, development stage and stimulus.
Inclusion or skipping of a 61-base pair (bp) exon in the 3 0 -end of casp-2 pre-mRNA leads to the formation of two mRNAs encoding the short and the long isoform of caspase-2, respectively (Wang et al., 1994; Cote et al., 2001a) . Insertion of the alternative exon 9 introduces a premature stop codon, which leads to production of caspase-2S (Wang et al., 1994; Cote et al., 2001b) . In addition, the two mRNAs differ at their 5 0 -end, upstream of the first exon common to both isoforms, which suggests the existence of distinct transcriptional initiation sites and/or alternative splicing events in this region. The initial survey of CASP-2 gene expression showed that the long isoform is the dominant form expressed in most tissues examined whereas the short isoform is predominantly expressed in heart, brain and skeletal muscle (Wang et al., 1994; Kumar et al., 1997) . In the course of rat brain development, casp-2S mRNA reaches similar amounts as casp-2L mRNA, and remains at this level in the adult tissue (Kojima et al., 1998) . Additional caspase-2 isoforms may also be derived from CASP-2 gene alternative splicing. For example, we have identified a truncated isoform, casp-2L-Pro, whose overexpression & 2003 Nature Publishing Group All rights reserved 0950-9232/03 $25.00 www.nature.com/onc ONCOGENOMICS negatively interferes with apoptotic pathways (Droin et al., 2000) .
Caspases are synthesized as inactive proenzymes or procaspases (Nicholson, 1999) . These proenzymes must be cleaved at key conserved aspartate residues to be activated. Upon activation, the 48-kDa procaspase-2 is processed in two subunits of 18 and 14 kDa (Li et al., 1997; Colussi et al., 1998a; Paroni et al., 2001) . This activation occurs in many cell types in response to various apoptotic stimuli, including growth factor withdrawal, cytotoxic drug or death receptor ligand treatment, and antigen receptor ligation (Harvey et al., 1996; Stefanis et al., 1998; Droin et al., 2001b) . Golgin-160 has been identified as a true caspase-2 substrate (Mancini et al., 2000) . However, the exact function of this enzyme in apoptosis and other biological processes is not completely understood. For example, whether caspase-2 acts upstream or downstream in the caspase cascade remains a matter of controversy despite the fact that it belongs to the group of caspases with a long prodomain that function mainly as initiators of the proteolytic cascade (Nicholson, 1999; Paroni et al., 2001) . Procaspase-2 can undergo oligomerization and autoactivation through its prodomain (Butt et al., 1998; Colussi et al., 1998b) . Through its large amino-terminal caspase recruitment domain (CARD), it interacts with the adaptor protein RAIDD (RIP-associated Ichlhomologous protein with a death domain) following engagement of some death receptors (Ahmad et al., 1997; Duan and Dixit, 1997; Droin et al., 2001a) . Caspase-2L overexpression can trigger the translocation of Bid to the mitochondria and cytochrome c release from this organelle (Sato et al., 1997; Swanton et al., 1999; Paroni et al., 2001; Guo et al., 2002; Paroni et al., 2002) . Caspase-2 also plays a role as an effector caspase following activation by other proteases, such as caspase-3 or the serine protease granzyme B (Allet et al., 1996; Ahmad et al., 1997; Li et al., 1997; Thornberry et al., 1997; Slee et al., 1999) .
Procaspase-2 was identified in the cytosol and several cell compartments, including the mitochondria (Susin et al., 1999) , the nucleus (Colussi et al., 1998a, b; Shikama et al., 2001 ) and the Golgi apparatus (Mancini et al., 2000) depending on the differentiation status of the cells (Sordet et al., 2002) . The proenzyme could be activated in these various compartments, whereas the active enzyme could undergo translocation in response to apoptotic signals (Susin et al., 1999) and trigger cell death-related mitochondrial events either directly (Guo et al., 2002; Lassus et al., 2002; Robertson et al., 2002) or from the nucleus without relocalizing into the cytoplasm (Paroni et al., 2002) . Caspase-2 activity may be modulated by various interacting proteins, including proapoptotic caspase adaptor protein (PACAP) that specifically interacts with procaspase-2L (Bonfoco et al., 2001) and ISBP (IchlS-binding protein) that interacts with procaspase-2S (Ito et al., 2000) .
Very little information is available concerning the mechanisms of CASP-2 gene regulation. Upregulation of casp-2L mRNA was observed in the rat brain following transient ischemia (Asahi et al., 1997) whereas previous results from our group have suggested that casp-2S mRNA was upregulated in tumor cells exposed to the cytotoxic drug etoposide (Droin et al., 1998) . The transcriptional promoters of rat CASP-3 and CASP-9 genes have been recently described (Nishiyama et al., 2001; Liu et al., 2002) , but no human CASP gene promoter has been described so far. In the present study, we demonstrate that several mechanisms contribute to the synthesis of different caspase-2 isoforms, including two alternative splicing events at the pre-mRNA level and the use of distinct AUG initiating codons for each isoform with the short protein using two translation initiation sites. We also provide the first description of a 5.1 kb sequence located upstream of the first translated exon in a human caspase gene.
RESULTS

Casp-2L and Casp-2S cDNA sequences
Alignment of originally described human casp-2L (Ichl L ) and casp-2S (Ich-ls) cDNA sequences (Accession U13021 and U13022) shows a perfect identity from position 69 to position 929 in casp-2L sequence. Then, a 61-bp insertion is found in casp-2S cDNA. Subsequent sequences show a nearly perfect match until position 1550 in the casp-2L sequence, corresponding to the end (position 1456) of casp-2S cDNA, with a single base difference at position 1255 in the casp-2L sequence ( Figure 1a) . The 61-bp insertion in the casp-2S cDNA has been previously shown to result from an alternative splicing event whereby exon 9 is inserted specifically in casp-2S mRNA (Wang et al., 1994) .
Five variant (V1-V5) cDNA sequences have now been reported (Accession NM32982, NM001224, NM 032983, NM 032984, XM 036975, respectively). Three of them (V1, V3 and V5) are related to casp-2L (Figure 1b ) whereas the two other (V2 and V4) are related to casp-2S (Figure 1c) . Most of the point mutations described in these variants were identified in only one transcript sequence. However, some mutations could be more consistent, for example, at position 1255 in the 3 0 untranslated region of casp-2L.
Compared to the casp-2L cDNA sequence, V1 includes a 103 bp 5 0 extension, a 1381 bp 3 0 -extension and three point mutations (positions 130, 476 and 1255); V5 is characterized by a 52 bp 5 0 -extension, a 1362 bp 3 0 -extension and one point mutation (position 1255); V3 contains the 103 bp 5 0 -extension described in V1, a 1380 bp 3 0 -extension, two point mutations (positions 768 and 1255) and a 217 bp internal deletion (Figure 1b) . We have previously isolated and described a truncated casp-2L-like isoform, casp-2L-Pro, which corresponds to a partial V3-like mRNA (Sato et al., 1997) . A survey of the EST databases suggests that casp-2L transcripts could initiate at least 7 bp upstream of V1 5 0 -end (BG 397039, AW 503239) or even further upstream, at 69 bp of V1 5 0 -end (AL582071). V2 cDNA sequence is 100% identical with casp-2S with a 765 bp 3 0 -extension, whereas V4, which contains
Characterization of the 5 0 -end of the human CASP-2 gene E Logette et al the same 765 bp 3 0 -extension, is characterized by a 217 bp and a 60 bp internal deletions, two point mutations at positions 908 and 1032 and one single base deletion at position 1807 (Figure 1b) . The survey of EST databases does not bring in new information on the structure of casp-2S cDNA.
Procaspase-2L and procaspase-2S amino-acid sequences It has been reported previously, based on protein molecular weight and software-based analysis, that translation of casp-2L and casp-2S mRNAs was not interrupted by the same stop codon. Insertion of 61 bases in casp-2S mRNA induces a premature arrest in translation, leading to a shorter protein (Wang et al., 1994) . However, the site of translation initiation remained poorly defined.
The originally described casp-2L (Ich-1 L ) cDNA encodes a 435 amino-acid protein known as procaspase-2L (Figure 2a) . The common amino acids between the originally described sequence and those deduced from V1 and V5 variants are either 100% identical (V5) or differ by only one amino acid at position 159 (L to V in V1). The protein sequence deduced from V3 is strikingly different from the previous proteins in its first N-terminal 19 amino acids, which then differs from the originally described procaspase-2L sequence by three amino-acid changes (Figure 2a) .
Since the 5 0 -extension in V1 and V5 variants adds an upstream in phase ATG codon, the corresponding proteins may be longer, including 452 amino acids. Upon analysis of V1 and V5 cDNAs, it appeared that casp-2L mRNA contained three in-frame AUG initiation codons (Figure 2a) . None of these AUGs apparently matched the consensus ACCAUGG sequence identified by Kozak (1986) . In order to determine which AUG was used by the translation machinery, we mutated each of them in V5 cDNA and in vitro expressed these mutated cDNAs using rabbit reticulocyte lysates. Mutations in either of the first two ATGs had no effect on the amount or on the apparent molecular weight of the protein. In contrast, a mutation in the third ATG completely abolished procaspase-2L expression in reticulocyte lysates. Thus, the initial ATG codon in casp-2L mRNA is the third one. In addition, the ability of procaspase-2L to induce apoptosis was determined following transient transfection. As expected, overexpression of wild-type (wt) procaspase-2L induced roughly 15% apoptosis, a level similar to that attained upon treatment of the cells with anti-Fas Characterization of the 5 0 -end of the human CASP-2 gene E Logette et al receptor antibody in the presence of cycloheximide (21% apoptosis) used as a positive control in these experiments. An additive effect (31% apoptosis) was observed in procaspase-2L-transfected cells treated by Fas receptor activating agents (data not shown).
The 312 amino-acid procaspase-2S sequence was initially deduced from casp-2S (Ich-1 S ) cDNA ( Figure 2b ). The amino-acid sequence deduced from V2 cDNA is 100% identical. The sequence deduced from V4 cDNA is strikingly different in its first Nterminal 19 amino acids, then shows two amino-acid changes within its region of overlap with the previously described sequences and lastly extends the protein sequence by 106 amino acids ( Figure 2b ). Analysis of casp-2S cDNAs identified two in-frame ATG initiation codons ( Figure 2b ). It had been suggested that translation of this isoform was initiated at the first one. Reticulocyte lysate-driven translation of casp-2S mRNA showed production of a doublet of roughly 33-34 kDa ( Figure 2b ). Mutation of the first ATG prevented the synthesis of the largest protein product, whereas mutation of the second ATG prevented the production of the shorter peptide. These results indicate that both ATGs function as protein initiation sites for procaspase-2S synthesis. These observations were confirmed by transient transfection of cDNA expression vectors in HCT116 cells (Figure 2d ). The lower molecular weight protein was more abundant than the largest polypeptide, indicating that in the living cell, the 33 KDa procaspase-2S is the main protein of these isoforms. Procaspase-2S overexpression did not induce apoptosis, as expected, and no protection against apoptosis induction by Fas receptor activation was observed, either with wt or the M1 and M2 mutants (data not shown).
Isolation of the 5
0 -flanking region of the CASP-2 gene
The analysis of casp-2 cDNAs combined with data from human genome databases indicated that the CASP-2 gene might contain at least 12 exons. These include two distinct exons 1 as caspase-2L and caspase-2S isoforms differ at the level of their first exon. Since the 5 0 -portion of the CASP-2 gene and its 5 0 -flanking region in genomic DNA had not been reported, we performed a series of experiments to isolate these regions. Starting from exon 2 that contains both caspase-2L and caspase-2S ATG start codons, three steps were required to clone a 5.1 kb sequence from human genomic DNA. First, by using the Genome Walker kit from Clontech, we obtained a 620 bp fragment including 100 bp of perfect match with the known cDNA sequence from the CASP-2 gene exon 2 and 520 bp of unknown sequence (Figure 3a ). This fragment was subsequently used as a probe to screen a genomic library, in combination with a full-length cDNA probe. Nine recombinant phages were selected, which permitted to identify a 4-kb-long sequence at the 5 0 -end of the gene. This sequence was nearly identical with that of the human clone AC073342, with the exception of 2 bp from the 3 0 -portion of the fragment. Lastly, another 1140 bp fragment was isolated by direct PCR from human genomic DNA. In total, about 5.1 kb of sequence was isolated, upstream of exon 2 of the CASP-2 gene (Figure 3a) .
Analysis of this 5.1 kb sequence identified a 1883 bp intron between a 69 bp fragment identical with the first Figure 2 Alternative translation initiation of casp-2S mRNA at two AUG start sites. (a) Schematic alignment of protein sequences derived from initially described casp-2L cDNA (Procasp2 L ) and the three variants described in Figure 1 . (b) Schematic alignment of protein sequences derived from initially described casp-2S cDNA (Procasp2 S ) and the two variants depicted in Figure 1 . M indicates a methionine and its associated number relates to the various mutants tested in panels c and d. Other letters refer to amino-acid differences in some variants: V5-and V2-derived proteins are 100% identical with procaspase-2L and procaspase-2S, respectively, whereas V3 and V4 contain internal deletions. (c) Expression of wild-type and mutated V5 casp-2L cDNA in rabbit reticulocyte lysates. The three methionine residues (M) indicated in panel a were successively mutated. (d) Expression of wild-type and mutated V2 casp-2S cDNA in rabbit reticulocyte lysates. The methionine residues were either independently (M1, M2) or simultaneously (M1+M2) mutated. Controls correspond to empty plasmids. The lower panel shows the Western blot analysis from transfected HCT116 cell extracts Characterization of the 5 0 -end of the human CASP-2 gene E Logette et al noncoding exon in casp-2S mRNA and the second exon containing the two functional ATG start codons for caspase-2S translation. The 140 bp, noncoding first exon of casp-2L was located a further 1 kb distance upstream. These results indicate that, in addition to exon 9 alternative splicing, two other distinct splicing events may take place in the 5 0 -part of the gene to produce either casp-2L or casp-2S mRNAs (Figure 3b ).
Analysis of the 5
0 -end of casp-2L and casp-2S mRNAs Software analyses identified putative transcription start sites at positions À2615 (casp-2S) and À3310 bp (casp-2L) (Figure 4a ). In order to confirm the existence of active transcription start sites around positions À3310 and À2615, we subcloned 100 bp fragments encompassing these sites in the promoterless pGL3 enhancer vector. In this vector, insertion of a transcription start site is required to drive luciferase gene expression under the control of the SV40 enhancer. The DNA segment encompassing the À3310 position is extremely active at inducing luciferase transcription (Figure 4b ), whereas the DNA segment encompassing the À2615 position did not permit to obtain luciferase expression above background. It should be noted that, in this case, the background luciferase level obtained with the control vector was quite high, which may have hampered our ability to detect the activity of casp-2S start site. We then attempted to determine experimentally the location of the 5 0 -ends of casp-2L and casp-2S mRNAs. For this purpose, we first used 5 0 -RT-RACE-PCR with various specific primers from within exon 1S (casp-2S) or exon 2 (casp-2L) to amplify the 5 0 -flanking region of the casp-2 mRNA isoforms (Figure 4a ). This experiment extended V1 cDNA sequence by 21 bp. Since we used mRNA capped site-dependent amplification, identification of several extensions suggested that casp-2L transcripts could originate at more than one 5 0 -site. An EST survey also identified several sequences, the largest one (AW500166) extending the V1cDNA sequence by 62 bases. The existence of several transcription start sites was confirmed by performing an RNase protection assay using a probe encompassing positions À3320 to À3020 bp (Figure 4c ). According to this experiment, the two most efficiently used 5 0 -transcription sites (À3195 and À3175) map, respectively, 115 and 135 bp upstream of the 5 0 -end of V1 (À3310). Several other bands were identified by the RNase protection assay, suggesting that other initiation sites may exist (Figure 4c, d) .
The 5 0 RT-RACE-PCR analysis extended V2 cDNA sequence by 89 bp, indicating that neither the initially described casp-2S sequence nor V2 cDNA corresponded to full-length transcripts (Figure 4a ). RNase protection assays demonstrated that the main transcription start site was located at position À2585 (Figure 4c, d) . No EST sequence has been described to cover the 5 0 -end of casp-2S cDNA.
Altogether, these analyses demonstrate that several transcription start sites within a limited promoter region exist for casp-2L mRNA, whereas transcription of casp-2S mRNA starts from a major site.
Transcriptional activity of the promoter regions
To identify the putative promoter regions, we first conducted software analyses. A TATA box was located at position À2635, upstream of the first base of exon 2. 
Although less clearly defined, a TATA-less region was also identified roughly 700 bp upstream (Figure 4a ). Then we used a luciferase reporter assay to evaluate the transcriptional activity of the CASP-2 gene 5 0 -flanking region. We first tested a 1.4 kb fragment starting at À3970 and ending at position À2595, 40 bases downstream from the putative TATA box and 20 bases downstream of the casp-2S +1 site identified by software analysis (Figure 5a) . Initial experiments were performed in human HCT116 colon carcinoma cells (Figure 5b ). This fragment demonstrated a high level of luciferase activity that was roughly 50% that of the SV40 promoter in the pGL3pm vector. Deletion of 650 bp from the 5 0 -end led to a 32% decrease in activity. A set of additional 5 0 deletions, which removed the casp-2L +1 region but retained various lengths of the casp-2S promoter region, were produced. Removal of 800, 933, 1100 and 1250 bp led to a strong decrease in luciferase activity, by up to 92%, which was on average 5 times above background (pGL3basic vector). These observations agree to the notion that casp-2S promoter strength is much weaker than that of casp-2L. On the other hand, deletion of 430 bp, 3 0 from casp-2L first exon, which removed casp-2S +1 region, strongly increased the 0 RT-RACE-PCR analysis. Specific primers (arrowheads) from within exon 2 (casp-2L) or E1C2S (casp-2S) were used to amplify the 5 0 -flanking region of the CASP-2 gene. This method extended the initially described E1C2L by an additional 21 bp, whereas E1C2S was extended by another 89 bp. An EST further extended the 5 0 -end of E1C2L by 62 bp. The position of putative transcription start sites, as determined by software predictions, is identified as large open arrows at positions -2615 and -3310 bp. (b) Functional analysis of putative transcription start sites. The pGL3 vector was used for measuring luciferase activity after transient transfection in HCT116 cells. pGL3b: promoter-less luciferase vector; pGL3E: pGL3enhancer luciferase vector. Fragments (100 bp) of the 5 0 -region encompassing the putative transcription start sites were inserted into the pGL3E vector and assayed for luciferase activity in HCT116 cells. These regions covered positions À3371/À3271 and À2720/À2620 for the putative transcription start sites of casp-2L ('+1 2L') and casp-2S ('+1 2S'), respectively. Basal activities of pGL3b and pGL3E vectors were determined as controls. Numbers represent the mean 7 s.d. of at least three independent experiments. (c, d) RNase Protection Assay. Two probes (shown as A and B on panel d; double lines) were used for this assay. These probes overlapped with a portion of E1C2L and E1C2S and the putative transcription start sites for each mRNA, respectively. The reaction products were analysed by denaturing gel electrophoresis (panel c). Arrows in panels c and d show the positions of the transcription start sites. The lengths of the elongated mRNAs are indicated on the lower part of panel d and the length of the main elongated fragments is underlined Characterization of the 5 0 -end of the human CASP-2 gene E Logette et al luciferase activity, since this activity was almost twice that of pGL3pm vector. Lastly, two large fragments of 0.8 and 1.8 kb including the software-determined +1 position for casp-2L mRNA transcription demonstrated a functional activity similar to that of the first tested fragment. All these constructs were tested in two other cell lines, namely the K562 human leukemic cell line ( Figure 5c ) and the Hela cervix carcinoma cell line (Figure 5d ). The relative strength of the various constructs was comparable in the three cell lines, although their activity ratios to that of the pGL3pm vector were somewhat different.
Discussion
The aim of the present study was to obtain a comprehensive picture of the human CASP-2 gene structure and regulation. Although the mouse gene has been invalidated several years ago (Bergeron et al., 1998) , structural and functional information on the human gene has remained limited. The combination of previously published data (Wang et al., 1994; Cote et al., 200la, b ) and the present study shows that at least two alternative splicing events are required to generate the previously described long and short isoforms, with several potential transcriptional start sites for each mRNA. In addition, we show that two alternative translation initiation sites may be used to generate procaspases-2S. Thus, both alternative promoter/splicing and alternative initiation of translation regulate expression of the main caspase-2 isoforms. The human CASP-2 gene includes 12 exons. The first splicing event takes place at the 5 0 -end of the gene and determines which noncoding exon 1 will be included in casp-2 mRNA. At least two distinct mRNAs can be generated by alternative splicing of these noncoding Characterization of the 5 0 -end of the human CASP-2 gene E Logette et al exons to a common acceptor site located in the second exon (the first translated one). Inclusion of the most 5 0 exon 1 is used to generate casp-2L mRNA, which requires another splicing event leading to exon 9 skipping. The resulting mRNA encodes the long isoform of caspase-2 (Wang et al., 1994) . Inclusion of the second downstream noncoding first exon 1 (exon 2 of the gene) is associated with that of the 61-bp exon 9 in the mRNA, which modifies the open reading frame and generates a premature termination codon. A 100 bp element present in intron 10 has been shown to promote casp-2S exon 9 inclusion by acting as a decoy splice site acceptor and proteins that bind to this sequence can either promote or decrease exon 9 inclusion (Cote et al., 2001a, b) . A schematic organization of the CASP-2 gene locus encompassing all exons and introns is shown in Figure 6 .
One of the main biological functions of caspases is to mediate the proteolysis that characterizes programmed cell death. This death process is under complex regulation in which alternative pre-mRNA splicing plays an important role by generating protein isoforms often harboring opposite activities (for review, Jiang and Wu, 1999). For example, differential splicing of the Bclx gene that encodes members of the Bcl-2 protein family generates several protein variants including Bcl-x l that displays an antiapoptotic activity and Bcl-x S , which counteracts the effects of Bcl-x l (Boise et al., 1993) . Characterization of the 5 0 -region of the mouse bcl-x gene has identified five distinct promoters whose tissuespecific selection influences the outcome of the splicing process (Pecci et al., 2001) .
Alternative splicing of caspase-2 exon 9 was described initially (Wang et al., 1994) . We show here that alternative splicing that takes place in the 5 0 untranslated portion of the gene also contributes to the regulation of the caspase-2L/caspase-2S ratio. Interestingly, the two main splicing events that characterize CASP-2 gene regulation can occur independently since we have shown recently that the cytotoxic drug etoposide specifically induces exon 9 inclusion without influencing the splicing of the noncoding exon 1 in the 5 0 portion of the gene. This effect induces a decrease in casp-2L transcript and protein levels (Wotawa et al., 2002) .
The use of alternative translation initiation at multiple AUG start sites is another mechanism that possibly contributes to the synthesis of multiple protein isoforms. Such an alternative translation initiation was demonstrated to occur on several viral and eucaryotic mRNAs (for review, Willis, 1999) . In the present study, we used expression vectors mutated at each of the potential AUG start sites to show that caspase-2S can be synthesized from both the first and the second in -frame AUGs from its second exon. This raises the possibility that two closely related caspase-2S isoforms might be expressed in vivo. Accordingly, transfection of wild-type and mutated casp-2S cDNAs in colon cancer cells can lead to synthesis of one or both isoforms, depending on the presence or absence of the two AUG codons. On the other hand, the first AUG from exon 2 is the only one identified to be a functional start site for the caspase-2L isoform. Thus, in addition to alternative splicing of premRNA, alternative translation initiation contributes to the synthesis of various caspase-2 isoforms by generating two caspase-2S variants.
The structure of the 5 0 -end and the 5 0 -flanking region of the CASP-2 gene may account for the differential expression of casp-2L and casp-2S mRNAs. Both noncoding first exons for casp-2L and casp-2S, in virtue of their differences in sequence and length, may play a role in the respective amounts and/or stability of the transcripts (Pecci et al., 2001 ). In addition, RNase protection assays identified several transcription start sites for the production of these transcripts. These include one major transcriptional start site for casp-2S mRNA and several start sites for casp-2L mRNA, among which two major sites could be found. Transient transfection with serial 5 0 deletions, with the largest removing the start site used to generate casp-2L mRNA, demonstrated that the casp-2L promoter region has a much stronger transcriptional activity than that of Figure 6 Schematic representation of the CASP-2 gene and its two main isoforms. Representation of CASP-2L and CASP-2S exon/ intron organization as well as presumptive splicing events. The gene contains 12 exons, among which the first exon differs between the two isoforms and is noncoding, and the ninth is incorporated only in casp-2S mRNA. This schematic is adapted with permission from the Ensembl genome group (www.ensembl.org)
Characterization of the 5 0 -end of the human CASP-2 gene E Logette et al casp-2S, in good agreement with the respective expression levels of the caspase isoforms (Wang et al., 1994) . The relative activity of promoter constructs are comparable among several cell lines of distinct tissue origin. However, some quantitative differences can be observed, indicating that the relevant trans-acting factors might differ in their content or activity between cells. Recent studies have revealed novel insights in the biological functions of caspase-2, including the ability of the protein to regulate cell death from the nucleus (Paroni et al., 2001; Lassus et al., 2002; Robertson et al., 2002) and the enzyme interaction with cyclin D3 that connects cell proliferation and cell death machineries (Mendelsohn et al., 2002) . We have shown here that alternative transcription and translation of the CASP-2 gene might potentially give rise to a series of variant proteins. Future studies may delineate the biological functions of these isoforms, the role of specific transcription factors in CASP-2 gene expression and the influence of pathophysiological conditions upon CASP-2 gene regulation.
Materials and methods
Cell lines and culture
The human HCT116 colon carcinoma cells and the human leukemic HL60, U937 and K562 cell lines were obtained from the ATCC (Rockville, MD, USA). The Hela cell line was obtained from the ECACC (Salisbury, UK). Cell lines were maintained in Eagle's minimum essential medium (HCT116 and Hela) and RPMI 1640 (other cell lines) supplemented with 10% fetal calf serum, 2 mm l-glutamine, penicillin (l00 U/ml) and streptomycin (l00 mg/ml) at 371C in an atmosphere of 95% air and 5% CO 2 .
In vitro translation and Western blotting
In vitro translation was performed with a coupled transcription/translation reticulocyte lysate system (Promega, Charbonnie`res, France) according to the manufacturer's protocol. The desired cDNA sequences were cloned into the PCR-TOPO 2.1 or TOPO-II plasmid in front of the T7 promoter (Invitrogen, Paisley, Scotland) . Subconfluent HCT116 cells were harvested, washed twice in PBS and lysed in boiling buffer (1% SDS, 1 mm Na 3 VO 4 , 10 mm Tris pH 7.4) containing 0.1 mm PMSF, 10 mg/ml aprotinin and 5 mg/ml leupeptin for 10 min at 41C. Equal amounts of proteins (or 10 ml reticulocyte lysate) were boiled in Laemli buffer for 5 min, separated by SDS-PAGE using 12% polyacrylamide gels and electroblotted onto PVDF membranes (BioRad, Ivry-sur-Seine, France). The membranes were incubated overnight at 41C with an anti-human procaspase-2 monoclonal antibody (Pharmingen, Pont de Claye, France) that recognizes both the long and short isoforms of the protein, an anti-human PARP antibody (Roche, Meylan, France) or with an anti-human HSC70 (SantaCruz/ Tebu, Le Perrey en Yvelines, France) as a loading control. The blots were revealed using an Enhanced Chemioluminescence detection kit (Amersham) by autoradiography.
Apoptosis determination
HCT116 cells were treated with the CH11 anti-Fas receptor antibody (50 ng/ml) in the presence of cycloheximide (CHX, 0.8 mg/ml), conditions known to induce apoptosis (Micheau et al., 1999) , for 24 h. Transfected cells (see below) were treated similarly 24 h after transfection. Apoptosis was determined by Hoechst 33342 (1 mg/ml) staining the cells for 30 min at 371C, and fluorescence microscopy analysis of 200 cells per condition.
Library screening and genome walking
A lambda DashII genomic library (Stratagene, La Jolla, CA, USA) was plated and transferred onto Hybond-N nylon membranes (Amersham, Les Ulis, France) and was screened under conventional hybridization procedures. Extension from genomic DNA was performed with the Genome walker kit (Clontech/Ozyme, St Quentin en Yvelines, France) using downstream primers from the 5 0 -end of the casp-2 cDNA sequence and adapter primers. A partial genomic sequence corresponding to the first intron of the CASP-2 gene was originally isolated and submitted to Genbank (Accession # AF283569). The complete sequence of the isolated genomic fragments was determined, and found to match nearly perfectly with the sequence from BAC clone AC073342. Two adjacent base pairs from the downstream portion of the first intron of CASP-2 gene were found to be divergent, possibly corresponding to a polymorphism.
RNA preparation and RT-PCR analysis
Total RNA was isolated with the 'nucleospin RNA' extraction kit (Macherey-Nagel, Hoerdt, France). RNA (500 ng) was reverse transcribed and then amplified in one step with the 'QIAGEN OneStep RT-PCR' kit (Qiagen, Courtabeuf, France). The identity of each PCR-generated product with its corresponding cDNA was confirmed by sequencing. Sense and antisense primers used to amplify human cDNAs were as follows: casp-2L forward primer: 5 0 -ATGGCCGCTGA-CAGGGGACGC-3 0 , reverse primer: 5 0 GGCAGCAAGTT-GAGGAGTTC 3 0 and casp-2S forward primer: 5 0 GGGAGGGAACGATTTAAGGA-3 0 , reverse primer: 5 0 CCAGAAGATGTTCTAACAATTCGCTC 3 0 . The casp-2L and casp-2S cDNAs were amplified for 25 and 32 PCR cycles, respectively.
The 5 0 -ends of casp-2 mRNAs were isolated by 5 0 RACE using the 'FirstChoice RLM-RACE' Kit (Ambion, Montrouge, France). Total RNA was isolated by cesium chloride centrifugation, and 10 mg RNA were treated by phosphatase to remove free 5 0 -phosphates from rRNA, tRNA, DNA and degraded mRNA, leaving intact the cap structure from intact 5 0 -mRNA ends. RNA was then treated with a pyrophosphatase to remove the cap structure from full-length mRNAs. A 45-base RNA adapter oligonucleotide was ligated to the decapped mRNA population using a T4 RNA ligase. A random primer reverse transcription reaction and nested PCR with the adapter primer and a specific primer were used to amplify 5 0 -ends of casp-2 transcripts. The amplification products were analysed on 1% agarose gels with ethidium bromide staining and sequenced. The specific primers used to amplify the 5 0 -ends of casp-2 mRNA and their positions are indicated in Table 1 .
RNase protection assays (RPA)
The transcription start points were determined by RPA using the RiboQuant Ribonuclease Protection Assay Kit (Pharmingen). The cDNA fragments of interest were amplified by PCR Characterization of the 5 0 -end of the human CASP-2 gene E Logette et al and subcloned into the PCR TOPO-II plasmid (Invitrogen). The plasmid template, which contains the T7 bacteriophage promoter, was used for the synthesis of a radiolabeled antisense RNA probe. Two probes were constructed: the first 300 nt cRNA probe encompassing nucleotides(nt) À3320 to À3020, which includes part of the first noncoding exon of casp-2L mRNA, and the second 810 nt cRNA probe encompassing nt À2720 to À1910, which includes part of the first noncoding exon of casp-2S mRNA. The probes were then hybridized overnight in excess to 20 mg of total RNA in solution, after which the free probe and other single-stranded RNAs were digested by RNases. After proteinase K treatment, the remaining RNase-protected probes were purified and resolved on denaturing 6% polyacrylamide gels.
Plasmid vectors
Putative promoter-containing fragments were inserted into the pGL3-basic (pGL3b, Promega) vector. Putative transcriptional start site-containing fragments were cloned into the pGL3-enhancer (pGL3E) vector. Caspase expression vectors were constructed by inserting cDNAs into the pTarget plasmid (Promega). Progressive deletion constructs of the CASP-2 gene 5 0 -flanking region were produced by PCR. Sequences of primers used are shown in Table 1 . These primers also contain Kpn1 and Xho1 or BglII restriction enzyme sites to facilitate subsequent cloning steps. All plasmids were purified with 'Nucleobond ax' extraction kits (Macherey-Nagel) and verified by sequencing.
Transient transfections
Functional promoter activity of the 5 0 -flanking region of the CASP-2 gene was analysed using pGL3 luciferase-reporter vectors. The pRSV-b-galactosidase reporter vector was used as an internal control for normalization of transfection efficiencies. HCT116 and K562 cell lines were seeded into 24-well plates at a density of 100 000 cells/well 16 h before transfection by the 'Lipofectamine plus reagent' (Invitrogen) according to the manufacturer's instructions. A measure of 100 ng of each test plasmid and 20 ng of pRSV-b-galactosidase reporter vector were used for each experiment. U937, HL60 and Hela cells were transfected under the same conditions with the 'XtremeGENE Q2 transfection reagent' kit (Roche). After 24 h, cells were harvested and lysates were analysed for luciferase and b-galactosidase activities using the 'Luciferase Assay Reagent' and the 'b-galactosidase Enzyme Assay System' (Promega) and a luminometer (Lumat LB 9507, EG&G Berthold). Caspase expression vectors were introduced into the cells under the same conditions. Cells were lysed 24 h after transfection and protein expression was analysed by Western blotting.
Site-directed mutagenesis
Point mutations were introduced into caspase-2 expression vectors with the 'QuickChange site-directed mutagenesis' kit (Stratagene) according to the manufacturer's instructions. Expression vectors (40 ng) were used with the relevant oligonucleotides and PCR was performed for 16 cycles. The mutations were detected by sequencing. Primers used for 
